Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pulmonary Circulation|November 26, 2020
Evaluation of code-based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databasesViviane P Sprecher, Eva-Maria Didden, Joel N Swerdel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 26, 2023
Efficacy and Safety of Moxidectin-Albendazole and Ivermectin-Albendazole Combination Therapy Compared to Albendazole Monotherapy in Adolescents and Adults Infected with Trichuris trichiura: A Randomized, Controlled Superiority TrialViviane P Sprecher, Jean T Coulibaly, Eveline Hürlimann, et al.
NPJ Biofilms and Microbiomes|May 28, 2026
Combined high-quality metagenomics reveals off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteriaJulian Dommann, Viviane P Sprecher, Christian Beisel, et al.
The Lancet. Infectious Diseases|November 10, 2023
Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trialViviane P Sprecher, Daniela Hofmann, Vanthanom Savathdy, et al.
The Lancet. Infectious Diseases|July 17, 2025
Efficacy and safety of moxidectin-albendazole combination therapy for Trichuris trichiura infections in school-aged children: a double-blind, randomised, controlled, superiority trialAnnina Schnoz, Viviane P Sprecher, Stefan Biendl, et al.
The Lancet. Infectious Diseases|September 20, 2025
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a single-blind, randomised, controlled, dose-ranging, phase 2 trialViviane P Sprecher, Annina Schnoz, Stefan Biendl, et al.
Pageof 1